Johnson & Johnson's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 17 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 223.53.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
The current financial score of Johnson & Johnson is 7.49, ranking 111 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 24.56B, representing a year-over-year increase of 9.08%, while its net profit experienced a year-over-year increase of 49.11%.
Key Metrics
The current valuation score of Johnson & Johnson is 7.77, ranking 47 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 20.64, which is 69.21% below the recent high of 34.92 and 54.14% above the recent low of 9.47.
The current earnings forecast score of Johnson & Johnson is 7.50, ranking 104 out of 159 in the Pharmaceuticals industry. The average price target is 205.00, with a high of 230.00 and a low of 170.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Johnson & Johnson is 9.72, ranking 2 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 237.22 and the support level at 209.56, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Johnson & Johnson is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 75.07%, representing a quarter-over-quarter increase of 0.85%. The largest institutional shareholder is The Vanguard, holding a total of 235.57M shares, representing 9.78% of shares outstanding, with 0.98% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Johnson & Johnson is 9.95, ranking 1 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
